Efficacy of etravirine for treatment of acute HIV meningoencephalitis

Clinical Infectious Diseases

Volumn 48, Issue 6, 2009, Pages

  Couzigou, Carine ^a,b,c   Seang, Sophie ^a,c   Morand Joubert, Laurence ^d   Roque Afonso, Anne Marie ^b,c   Escaut, Lélia ^a,c   Vittecoq, Daniel ^a,c  

^a pital Paul Brousse   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDAZINE DERIVATIVE;

ACUTE HIV MENINGOENCEPHALITIS; ADD ON THERAPY; ADULT; AMNESIA; ANAMNESIS; ANTIVIRAL RESISTANCE; ARTICLE; ASTHENIA; BRAIN ATROPHY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CYTOLYTIC HEPATITIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MENINGOENCEPHALITIS; MIXED INFECTION; MUTATIONAL ANALYSIS; NEPHROLITHIASIS; NIGHTMARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; TREMOR; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; CEREBROSPINAL FLUID; ISOLATION AND PURIFICATION; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CEREBROSPINAL FLUID; FEMALE; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; MENINGOENCEPHALITIS; PYRIDAZINES; TREATMENT OUTCOME;

EID: 62449102858     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597109     Document Type: Article

References (13)

1. von Giesen HJ, Köller H, Theisen A, Arendt G. Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-l-infected patients. J Acquir Immune Defic Syndr 2002;29:363-7.
2. HIV French Resistance. HIV-1 genotypic drug resistance interpretation's algorithms. July 2007. Available at: http://www.hivfrenchresistance.org. Accessed 1 February 2009.
3. Price RW. The two faces of cerebrospinal fluid (CSF) HIV infection? Trends Microbiol 2000;8:387-90.
4. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
5. McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006;7:142-53.
6. Enting RH, Hoetelmans RM, Lange JM, et al. Antiretroviral drugs and the central nervous system. AIDS 1998;12:1941-55.
7. Madruga JV Cahn P, Grinsztejn B, et al.; DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-l- infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
8. Lazzarin A, Campbell T, Clotet B, et al.; DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-l- infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
9. Vingerhoets I, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2 [abstract 32], In: Program and abstracts of the 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications (Barbados, West Indies). Antivir Ther 2007;(Suppl 1):S34.
10. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS 2008;22:989-90.
11. Letendre S, Paulino AD, Rockenstein E, et al.; HIV Neurobehavioral Research Center Group. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007; 196: 361-70.
12. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005;41:1787-93.
13. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV- 1-infected patients receiving combination therapy. I Infect Dis 1999; 180:862-4.